Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986310 +/- Nivolumab in Advanced Solid Tumors
NCT03661632Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ONO-4578 in solid tumor (advanced stage), muscle-invasive bladder cancer (MIBC), renal cell carcinoma (RCC) and 3 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events up to 3 years, Incidence of Serious Adverse Events up to 3 years and 4 more. Started Sep 2018; status: completed.
02
Drugs
ONO-4578
03
Conditions
solid tumor (advanced stage)muscle-invasive bladder cancer (MIBC)renal cell carcinoma (RCC)melanomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03661632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661632.